ADAP
Income statement / Annual
Last year (2023), Adaptimmune Therapeutics plc's total revenue was $60.28 M,
an increase of 122.05% from the previous year.
In 2023, Adaptimmune Therapeutics plc's net income was -$113.87 M.
See Adaptimmune Therapeutics plc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
06/30/2015 |
06/30/2014 |
| Operating Revenue |
$60.28 M
|
$27.15 M
|
$6.15 M
|
$3.96 M
|
$1.12 M
|
$59.51 M
|
$37.83 M
|
$14.20 M
|
$10.72 M
|
$604,625.00
|
| Cost of Revenue |
$9.86 M |
$127.73 M |
$111.09 M |
$91.57 M |
$97.50 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$50.42 M |
-$100.58 M |
-$104.94 M |
-$87.61 M |
-$96.38 M |
$59.51 M |
$37.83 M |
$14.20 M |
$10.72 M |
$604,625.00 |
| Gross Profit Ratio |
0.84 |
-3.7 |
-17.07 |
-22.13 |
-85.9 |
1 |
1 |
1 |
1 |
1 |
| Research and Development
Expenses |
$126.51 M
|
$127.73 M
|
$111.09 M
|
$91.57 M
|
$97.50 M
|
$98.27 M
|
$87.39 M
|
$63.79 M
|
$23.19 M
|
$12.53 M
|
| General & Administrative
Expenses |
$71.81 M
|
$63.39 M
|
$57.31 M
|
$45.80 M
|
$43.39 M
|
$43.60 M
|
$31.11 M
|
$23.21 M
|
$11.32 M
|
$2.73 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$71.81 M
|
$63.39 M
|
$57.31 M
|
$45.80 M
|
$43.39 M
|
$43.60 M
|
$31.11 M
|
$23.21 M
|
$11.32 M
|
$2.73 M
|
| Other Expenses |
$0.00 |
-$536,000.00 |
$3.85 M |
$1.16 M |
$75,000.00 |
-$15.50 M |
$8.74 M |
$1.00 M |
-$726,495.05 |
-$281,023.27 |
| Operating Expenses |
$188.42 M |
$191.11 M |
$168.40 M |
$137.36 M |
$140.89 M |
$141.87 M |
$118.49 M |
$87.00 M |
$33.79 M |
$14.98 M |
| Cost And Expenses |
$198.28 M |
$191.11 M |
$168.40 M |
$137.36 M |
$140.89 M |
$141.87 M |
$118.49 M |
$87.00 M |
$33.79 M |
$14.98 M |
| Interest Income |
$5.96 M |
$1.54 M |
$1.10 M |
$2.31 M |
$2.77 M |
$2.85 M |
$2.23 M |
$1.11 M |
$787,000.00 |
$3,406.34 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$376,000.00 |
$2.23 M |
$0.00 |
$0.00 |
$6,812.69 |
| Depreciation &
Amortization |
$9.84 M
|
$6.07 M
|
$6.57 M
|
$7.65 M
|
$8.04 M
|
$7.81 M
|
$5.42 M
|
$3.29 M
|
$732,785.00
|
$250,366.00
|
| EBITDA |
-$128.20 M
|
-$155.59 M
|
-$155.68 M
|
-$125.81 M
|
-$131.76 M
|
-$74.56 M
|
-$75.24 M
|
-$69.51 M
|
-$23.77 M
|
-$23.91 M
|
| EBITDA Ratio |
-2.13 |
-5.82 |
-25.32 |
-31.79 |
-117.43 |
-1.25 |
-1.99 |
-4.9 |
-2.04 |
-23.35 |
| Operating Income Ratio
|
-2.29
|
-6.04
|
-26.39
|
-33.71
|
-124.57
|
-1.38
|
-2.13
|
-5.13
|
-2.15
|
-23.77
|
| Total Other
Income/Expenses Net |
$25.50 M
|
-$1.29 M
|
$4.95 M
|
$3.48 M
|
$2.85 M
|
-$12.65 M
|
$10.97 M
|
$2.11 M
|
-$3.19 M
|
$2.83 M
|
| Income Before Tax |
-$112.54 M |
-$162.96 M |
-$157.30 M |
-$129.93 M |
-$136.92 M |
-$95.02 M |
-$69.69 M |
-$70.69 M |
-$23.69 M |
-$14.37 M |
| Income Before Tax Ratio
|
-1.87
|
-6
|
-25.58
|
-32.83
|
-122.03
|
-1.6
|
-1.84
|
-4.98
|
-2.21
|
-23.77
|
| Income Tax Expense |
$1.34 M |
$2.50 M |
$791,000.00 |
$162,000.00 |
$242,000.00 |
$497,000.00 |
$451,000.00 |
$892,000.00 |
-$2.11 M |
-$1.67 M |
| Net Income |
-$113.87 M |
-$165.46 M |
-$158.09 M |
-$130.09 M |
-$137.17 M |
-$95.51 M |
-$70.14 M |
-$71.58 M |
-$21.59 M |
-$12.70 M |
| Net Income Ratio |
-1.89 |
-6.09 |
-25.71 |
-32.87 |
-122.25 |
-1.61 |
-1.85 |
-5.04 |
-2.01 |
-21.01 |
| EPS |
-0.0944 |
-0.17 |
-0.17 |
-0.15 |
-0.22 |
-0.16 |
-0.13 |
-0.17 |
-0.1 |
-0.0417 |
| EPS Diluted |
-0.0944 |
-0.17 |
-0.17 |
-0.15 |
-0.22 |
-0.16 |
-0.13 |
-0.17 |
-0.1 |
-0.0417 |
| Weighted Average Shares
Out |
$1.21 B
|
$967.24 M
|
$934.83 M
|
$854.78 M
|
$629.81 M
|
$584.34 M
|
$527.64 M
|
$424.71 M
|
$214.70 M
|
$304.33 M
|
| Weighted Average Shares
Out Diluted |
$1.21 B
|
$967.24 M
|
$934.83 M
|
$854.78 M
|
$629.81 M
|
$584.34 M
|
$527.64 M
|
$424.71 M
|
$214.70 M
|
$304.33 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
